Naproxen for presymptomatic Alzheimer disease: Is this the end, or shall we try again?

Affiliations

¹ From the Department of Neurology (L.A.H.), University of Oklahoma Health Sciences Center, Oklahoma City; and Departments of Neurology, Psychiatry & Behavioral Sciences, and Epidemiology & Population Health (R.B.L.), Albert Einstein College of Medicine, Bronx, NY. linda-hershey@ouhsc.edu.
² From the Department of Neurology (L.A.H.), University of Oklahoma Health Sciences Center, Oklahoma City; and Departments of Neurology, Psychiatry & Behavioral Sciences, and Epidemiology & Population Health (R.B.L.), Albert Einstein College of Medicine, Bronx, NY.

Editorial

Linda A Hershey et al. Neurology. 2019.

. 2019 Apr 30;92(18):829-830.

doi: 10.1212/WNL.0000000000007233. Epub 2019 Apr 5.

¹ From the Department of Neurology (L.A.H.), University of Oklahoma Health Sciences Center, Oklahoma City; and Departments of Neurology, Psychiatry & Behavioral Sciences, and Epidemiology & Population Health (R.B.L.), Albert Einstein College of Medicine, Bronx, NY. linda-hershey@ouhsc.edu.
² From the Department of Neurology (L.A.H.), University of Oklahoma Health Sciences Center, Oklahoma City; and Departments of Neurology, Psychiatry & Behavioral Sciences, and Epidemiology & Population Health (R.B.L.), Albert Einstein College of Medicine, Bronx, NY.

No abstract available

Comment on

INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.
Meyer PF, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Magnan ME, Savard M, Rosa-Neto P, Poirier J, Etienne P, Breitner J; PREVENT-AD Research Group. Meyer PF, et al. Neurology. 2019 Apr 30;92(18):e2070-e2080. doi: 10.1212/WNL.0000000000007232. Epub 2019 Apr 5. Neurology. 2019. PMID: 30952794 Free PMC article. Clinical Trial.